Cargando…

Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease

Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) characterized by intestinal inflammation. Increased intestinal levels of the proinflammatory cytokine tumor necrosis factor-α (TNF-α) are associated with disease activity and severity. Anti-TNF-α therapy is admini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gareb, Bahez, Otten, Antonius T., Frijlink, Henderik W., Dijkstra, Gerard, Kosterink, Jos G. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356880/ https://www.ncbi.nlm.nih.gov/pubmed/32545207 http://dx.doi.org/10.3390/pharmaceutics12060539

Ejemplares similares

Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process
por: Gareb, Bahez, et al.
Publicado: (2019)

Capsules with Ileocolonic-Targeted Release of Vitamin B(2), B(3), and C (ColoVit) Intended for Optimization of Gut Health: Development and Validation of the Production Process
por: Ahmed, Aisha A., et al.
Publicado: (2023)

Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease
por: Otten, Antonius T., et al.
Publicado: (2022)

Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets
por: Maurer, Jacoba M., et al.
Publicado: (2015)

Association of tumor necrosis factor-α and -β gene polymorphisms in inflammatory bowel disease
por: Al-Meghaiseeb, Ebtissam Saleh, et al.
Publicado: (2016)

The Development and Implementation of Airflow Visualization Studies (“Smoke” Studies) as a Training Tool in Aseptic Hospital Compounding Facilities
por: Borgonje, Paula E., et al.
Publicado: (2022)

The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
por: Byun, Ja Min, et al.
Publicado: (2015)

Anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Ramakrishna, B.S.
Publicado: (2017)

Study of tumor necrosis factor receptor in the inflammatory bowel disease
por: Souza, Roberta Figueiroa, et al.
Publicado: (2023)

Hyperactive neutrophil chemotaxis contributes to anti‐tumor necrosis factor‐α treatment resistance in inflammatory bowel disease
por: Yau, Tung On, et al.
Publicado: (2022)

Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation
por: Sibum, Imco, et al.
Publicado: (2019)

Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration
por: Heida, Rick, et al.
Publicado: (2023)

Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis
por: Parekh, Ravish, et al.
Publicado: (2018)

Tumor necrosis factor α Inhibition for Alzheimer’s Disease
por: Chang, Rudy, et al.
Publicado: (2017)

Bottom-Up Preparation Techniques for Nanocrystals of Lipophilic Drugs
por: de Waard, Hans, et al.
Publicado: (2010)

1728. A Retrospective Analysis of 49 Cases of Histoplasmosis in Inflammatory Bowel Disease Patients on Tumor Necrosis Factor-α Antagonists
por: Harris, Courtney, et al.
Publicado: (2019)

High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists
por: Guo, Angela, et al.
Publicado: (2022)

The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-α
por: Ventin-Holmberg, Rebecka, et al.
Publicado: (2022)

Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer
por: Oosting, Linette T., et al.
Publicado: (2022)

Effects of ileocolonic delivered vitamin B(2), B(3) and C (ColoVit) or the Groningen anti-inflammatory diet on disease course and microbiome of patients with Crohn’s disease (VITA-GrAID study): a protocol for a randomised and partially blinded trial
por: Otten, Antonius Timotheus, et al.
Publicado: (2023)

Drug Content Effects on the Dispersion Performance of Adhesive Mixtures for Inhalation
por: Grasmeijer, Floris, et al.
Publicado: (2013)

Correction: Mixing Time Effects on the Dispersion Performance of Adhesive Mixtures for Inhalation
por: Grasmeijer, Floris, et al.
Publicado: (2013)

Mixing Time Effects on the Dispersion Performance of Adhesive Mixtures for Inhalation
por: Grasmeijer, Floris, et al.
Publicado: (2013)

Association of Tumor Necrosis Factor Alpha Gene Polymorphisms with Inflammatory Bowel Disease in Iran
por: NADERI, Nosratollah, et al.
Publicado: (2014)

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
por: Billmeier, Ulrike, et al.
Publicado: (2016)

Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
por: Pagnini, Cristiano, et al.
Publicado: (2019)

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease
por: Abdullah, Israa, et al.
Publicado: (2021)

Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors
por: Crispino, Federica, et al.
Publicado: (2023)

Intracolic ultrasound molecular imaging: a novel method for assessing colonic tumor necrosis factor-α expression in inflammatory bowel disease
por: Miao, Xiaoyan, et al.
Publicado: (2021)

Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
por: Lee, Ji Min, et al.
Publicado: (2022)

Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
por: Kang, Eun Ae, et al.
Publicado: (2022)

Pharmacokinetics of a Prototype Formulation of Sublingual Testosterone and a Buspirone Tablet, Versus an Advanced Combination Tablet of Testosterone and Buspirone in Healthy Premenopausal Women
por: van Rooij, Kim, et al.
Publicado: (2014)

A User-Friendly Model for Spray Drying to Aid Pharmaceutical Product Development
por: Grasmeijer, Niels, et al.
Publicado: (2013)

Automated Filling Equipment Allows Increase in the Maximum Dose to Be Filled in the Cyclops(®) High Dose Dry Powder Inhalation Device While Maintaining Dispersibility
por: Sibum, Imco, et al.
Publicado: (2020)

Polymer-conjugated inhibitors of tumor necrosis factor-α for local control of inflammation
por: Washburn, Newell R., et al.
Publicado: (2013)

Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
por: Lee, Way-Seah, et al.
Publicado: (2017)

Association of Anti–Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease
por: Cohen-Mekelburg, Shirley, et al.
Publicado: (2021)

Reversing the Inflammatory Process—25 Years of Tumor Necrosis Factor-α Inhibitors
por: Muth, Katharina N., et al.
Publicado: (2023)

NOTCH2 sensitizes the chondrocyte to the inflammatory response of tumor necrosis factor α
por: Canalis, Ernesto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9hapfetvpcqjp5rp4nsb51qhus